clinical trial · NCT07222553
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD
Amgen·phase2·not yet recruiting·n = 15
Immunoglobulin G4-related DiseaseInebilizumab
brief summary
The primary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD), as well as to assess the safety and tolerability, of inebilizumab in pediatric participants with IgG4-RD.
started
Apr 3, 2026
primary completion
Jun 10, 2031
completion
Jun 10, 2031
last updated
Dec 22, 2025
official title
Open-label, Uncontrolled, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Children From 2 Years to Less Than 18 Years of Age With Immunoglobulin G4-related Disease (IgG4-RD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol